Capecitabine Alternatives Compared
| Capecitabine | Opdivo (nivolumab) | Opdivo Qvantig (hyaluronidase / nivolumab) |
|
|---|
| Capecitabine | Opdivo (nivolumab) | Opdivo Qvantig (hyaluronidase / nivolumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Colorectal Cancer, Breast Cancer - Metastatic, Stomach Cancer, Pancreatic Cancer, Breast Cancer, Esophageal Carcinoma, Anal Cancer, Non Small Cell Lung Cancer, Prostate Cancer, Renal... View more |
Prescription only
Opdivo is an immune checkpoint inhibitor that may be used to treat many different cancers including melanoma, bladder cancer, liver cancer, and lung cancer. Fatigue, skin conditions, a cough, upper... View more |
Prescription only
Prescribed for Colorectal Cancer, Esophageal Carcinoma, Gastric Cancer, Head and Neck Cancer, Hepatocellular Carcinoma, Melanoma, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Urothelial... View more |
Related suggestions Colorectal Cancer
Esophageal Carcinoma
Popular comparisons
|
|||||||||||||||||||||||
| More about Capecitabine | More about Opdivo (nivolumab) | More about Opdivo Qvantig (hyaluronidase / nivolumab) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Capecitabine has an average rating of 6.7 out of 10 from a total of 61 ratings on Drugs.com. 57% of reviewers reported a positive effect, while 26% reported a negative effect. |
Opdivo has an average rating of 5.8 out of 10 from a total of 94 ratings on Drugs.com. 52% of reviewers reported a positive effect, while 40% reported a negative effect. |
Be the first to share your experience with this drug. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Capecitabine side effects |
View all Opdivo side effects |
View all Opdivo Qvantig side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
N/A |
N/A |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Capecitabine prices |
View all Opdivo prices |
View all Opdivo Qvantig prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Xeloda |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
0.75 hours |
640.8 hours |
640.8 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 288 drugs are known to interact with Capecitabine:
|
A total of 588 drugs are known to interact with Opdivo:
|
A total of 661 drugs are known to interact with Opdivo Qvantig:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
April 30, 1998 |
December 22, 2014 |
December 27, 2024 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.